Clinical trials: Malignancies Multiple
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected Tyrosine Kinase Inhibitor (TKI) for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP.
- Trial name
- NCT04971226
- Testing
- Imatinib, Nilotinib, Bosutinib
- Where
- 110 sites in United States, Australia and 27 more
- Volunteers
- 405 people
- Sponsor
- Novartis Pharmaceuticals
Prostatectomy, Oligometastatic Prostate Cancer
The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer
This randomized, controlled, multi-center clinical trial aims to evaluate the efficacy and safety of prostatectomy for castration-Naive oligometastatic prostate cancer
- Conditions
- Prostatectomy, Oligometastatic Prostate Cancer, Abiraterone
- Trial name
- NCT04992026
- Testing
- robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection, 1.Abiraterone Acetate Tablets, Prednisone Acetate Tablets
- Where
- China
- Volunteers
- 130 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lymphoma, Multiple Myeloma
Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy
The purpose of this study is to determine whether adults with hematologic malignancies on active systemic therapy or shortly after bone marrow transplantation need one or two doses of adjuvanted vaccine to achieve best possible…
- Conditions
- Lymphoma, Multiple Myeloma, Influenza A Virus, H1N1 Subtype
- Trial name
- NCT01016548
- Testing
- AS03-adjuvanted H1N1 pandemic influenza vaccine
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- University Health Network, Toronto
Multiple Myeloma, Auto Stem Cell Transplant
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
High dose chemotherapy with stem cell transplantation is commonplace in the treatment of multiple myeloma. This treatment uses a chemotherapy drug called Melphalan that has been used in several thousand bone marrow transplant…
- Trial name
- (Mel/MelVel) (NCT01241708)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Hackensack Meridian Health
Multiple Myeloma
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have…
- Trial name
- NCT00869232
- Testing
- Velcade, Melphalan, Thalidomide
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Arkansas
Refractory Multiple Myeloma
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
The study is designed as a multicenter, non-randomized, Phase II trial with one treatment arm. A total of 82 patients of both genders and older than 18 years with relapsed/refractory multiple myeloma are planned to be included in…
- Trial name
- NCT03731832
- Testing
- MLN9708, Pomalidomide 4 MG Oral Capsule, Dexamethasone
- Where
- 11 sites in Germany
- Volunteers
- 66 people
- Sponsor
- GWT-TUD GmbH
Castleman Disease, Multicentric Castleman Disease
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Background: Kaposi's sarcoma-associated herpes virus (KSHV)-associated multicentric Castleman disease (KSHV-MCD) is caused by a herpes virus known as KSHV.
- Conditions
- Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
- Trial name
- NCT01441063
- Testing
- Zidovudine, Tocilizumab, Valganciclovir (VGC)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neuroendocrine Tumor With Liver Metastases
Lenvatinib Plus Chemotherapy for pNET Liver Metastases
This prospective, non-randomized, concurrent parallel-controlled study will evaluate treatment response and resistance mechanisms in patients with pancreatic neuroendocrine tumors with liver metastases (pNET-LM) receiving…
- Trial name
- LEN-pNET (NCT07835893)
- Testing
- Lenvatinib, Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
Imagio Feasibility Multi-Reader, Multi-Case Study
Controlled, blinded, multi-reader, multi-case study
- Trial name
- NCT03708393
- Testing
- Imagio (IUS+OA), Imagio Ultrasound, Mammography
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Seno Medical Instruments Inc.
HER2-positive Breast Cancer, Male Breast Cancer
Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
The purpose of this study is to look at the safety and immune response to a vaccine used in patients previously treated for HER2 (human epidermal growth factor receptor 2) positive breast cancer.
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT01632332
- Testing
- HER-2/neu peptide vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Actinic Keratosis (AK)
A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period
Once or twice daily 12 week treatment in patients with Actinic Keratosis randomized to treatment in one of four arms.
- Trial name
- NCT03116698
- Testing
- Low dose DFD07 once daily, High dose DFD07 once daily, High dose DFD07 twice daily
- Where
- 20 sites in United States
- Volunteers
- 240 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Multiple Myeloma (MM)
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
This is a single-arm, open-label, single-center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of QI-019A in patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT07429721
- Testing
- QI-019A Injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cognitive Impairment, Hematologic Malignancy
Diet and Cognitive Training in Hematologic Cancer Survivors
The goal of this clinical trial is to examine feasibility of a cognitive intervention program in blood cancer survivors. The main questions it aims to answer are: is it feasible to combine a ketogenic diet supplementation and…
- Trial name
- NCT05708716
- Testing
- Modified ketogenic diet using an exogenous ketogenic formula, Online cognitive training
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Alabama at Birmingham
Actinic Keratosis
Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis
This study evaluate the efficacy and safety of ingenol mebutate gel 0.015% on face and scalp \& 0.05% on trunk and extremities in Korean patient with actinic keratosis.
- Trial name
- NCT02716714
- Testing
- ingenol mebutate gel 0.015%, ingenol mebutate gel 0.05%
- Where
- South Korea
- Volunteers
- 77 people
- Sponsor
- Korea University
Neoplasms
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
This is a Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with small cell lung cancer or squamous non-small cell lung cancer who have…
- Trial name
- NCT04350463
- Testing
- CC-90011, Nivolumab
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 92 people
- Sponsor
- Celgene
Multiple Myeloma
Finistere Myeloma Observatory (OMYFIN)
Current molecular risk stratification of multiple myeloma (MM), based on the presence of t(4 ;14) and 17p deletion, cannot fully explain treatment outcome heterogeneity, as other features also predict prognosis.
- Trial name
- OMYFIN (NCT06552221)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest
Multiple Myeloma, Non-Hodgkin's Lymphoma
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
The primary purpose of this Phase I study is to evaluate the effect of the co-administration of CYP3A4 inducers on the pharmacokinetics profile of VELCADE (bortezomib).
- Trial name
- NCT00608907
- Testing
- bortezomib, bortezomib, rifampicin, bortezomib, dexamethasone
- Where
- 9 sites in Israel, Italy and 3 more
- Volunteers
- 61 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Myeloma
Non-invasive MRD Assessment in Multiple Myeloma
The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously…
- Trial name
- NIRVANA (NCT05625971)
- Testing
- MRD Assessment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Rajshekhar Chakraborty, MD
Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
The purpose of the study is to evaluate the pharmacokinetic (PK) equivalence of Bmab1800 as compared with reference product Keytruda® in a randomized, double-blind, two-arm, parallel comparative, multi-center study in patients…
- Trial name
- NCT07581509
- Testing
- Bmab1800, US-Licensed Keytruda
- Where
- Brazil
- Volunteers
- 138 people
- Sponsor
- Biocon Biologics UK PLC
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination…
- Conditions
- Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
- Trial name
- NCT06827236
- Testing
- BNT323, BNT327
- Where
- 81 sites in United States, Australia and 9 more
- Volunteers
- 380 people
- Sponsor
- BioNTech SE
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.